Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rubicon targets Europe for "smallest" embolic filter:

This article was originally published in Clinica

Executive Summary

Rubicon Medical plans to begin clinical studies by the first quarter of 2003 to support a European CE-marking application to use its Rubicon embolic filter in patients with saphenous vein grafts, whereby vessel blockages have reappeared following heart bypass. The device, which is claimed to be smaller and easier to insert into blood vessels than rival devices, targets a potential $1bn worldwide market, says Rubicon. The Salt Lake City, Utah firm will also seek US FDA approval for the device following completion of the European studies.

You may also be interested in...



Resolving Botanicals Deadlock 'Not A Priority' For European Commission

Tensions between industry and the European Commission on the issue of  health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future. 

Hikma’s Vascepa Launch Strategy ‘Can Cause Market Confusion’

Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.

Germany Approves Unified Patent Court Ratification Bill

The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.

Topics

UsernamePublicRestriction

Register

OM016193

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel